You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.
The test is used to identify NSCLC patients for whom treatment with Tarceva in first-line therapy and Tagrisso in second and subsequent lines of therapy may be effective.
Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.
With the help of a newly generated gene regulatory network for T-cell differentiation, researchers identified transcription factors with ties to disease symptoms.
The company's EndoPredict test, launched in 2011, uses cancer gene expression profiling in combination with standard prognostic factors to assess relapse risk in breast cancer patients.
Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.
In PLOS this week: novel RIG-I-like receptor regulators, approach for identifying adaptive genes, and more.
New research suggests Ebola virus may appear in survivor sperm samples some nine months after disease onset, though sexual transmission appears relatively rare.
A majority of respondents said liquid biopsy is poised to become a widely used tool for assessing cancer mutations within the next one to four years, with NGS-based analysis preferred over other testing modalities.
NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.